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ABSTRACT 
Recently, the photomotor response (PMR) of zebrafish embryos was reported as a robust 
behavior that is useful for high-throughput neuroactive drug discovery and mechanism 
prediction. Given the complexity of the PMR there is a need for rapid and easy analysis of the 
behavioral data. In this study, we developed an automated analysis workflow using the KNIME 
Analytics Platform and made it freely accessible. This workflow allows to simultaneously 
calculate a behavioral fingerprint for all analyzed compounds and to further process the data. 
Furthermore, to further characterize the potential of PMR for mechanism prediction, we 
performed PMR analysis of 767 neuroactive compounds covering 14 different receptor classes 
using the KNIME workflow. We observed a true positive rate of 25% and a false negative rate 
of 75% in our screening conditions. Among the true positives, all receptor classes were 
represented, thereby confirming the utility of the PMR assay to identify a broad range of 
neuroactive molecules. By hierarchical clustering of the behavioral fingerprints, different 
phenotypical clusters were observed that suggest the utility of PMR for mechanism prediction 
for adrenergics, dopaminergics, serotonergics, metabotropic glutamatergics, opioids, and ion 
channel ligands.  
 
INTRODUCTION 
In 2010, the photomotor response (PMR) of zebrafish embryos was reported for the first time 
as a robust behavior that allows high-throughput neuroactive drug discovery.1 This study by 
Kokel and colleagues thoroughly characterized the PMR as a stereotypic series of motor 
behaviors by zebrafish embryos in response to high intensity light pulses. The potential of a 
PMR-based behavioral assay was demonstrated in a chemical screen of 14 000 small molecules, 
identifying hundreds of PMR-modifying hits. As PMR is regulated by multiple 
neurotransmitter pathways, PMR-modifying molecules are considered to be neuroactive. 
Interestingly, PMR behavior was also proven to allow target identification of novel hits by co-
clustering of molecules with similar phenotypes and with known mechanism of action (MOA).1 
This characteristic of PMR can have a broad applicability when generating a large reference 
map of PMR phenotypes of small molecules with known MOA. Then, the MOA of an 
interesting hit or drug candidate can be predicted by co-clustering and a targeted approach of 
mechanistic investigation can be done. However, little is known about the predictive value of 
PMR phenotyping. It has only been characterized in part which neurological pathways can 
modify the PMR in a robust and distinct manner, and there has been no characterization of 
pathways that cannot. There has also been no characterization of the rate of false negatives. 
Thus, there is a need to further characterize the predictive value of the PMR. 
 
PMR is a very complex behavior to analyze and data is generated rapidly by video recording. 
Motion is recorded as a change in pixels continuously in time for 30 seconds for each well of a 
96-well plate. In our set-up, a time frame of 0.067 seconds was used. This implies that for each 
well, 448 data points are generated in 30 seconds. As replicate wells are used per condition and 
in case of screening, hundreds up to thousands of molecules are analyzed, an excess of data is 
rapidly generated. For example, this study resulted in more than 1.5 million data points for the 
analysis of only 767 compounds. Hence, there is a need for rapid and easy analysis of the 
behavioral data. 
 
In this study, we developed an automated workflow for PMR analysis using the KNIME 
Analytics Platform (http://www.knime.org).2 This is an open-source integration platform 
providing a powerful and flexible workflow system combined with data analytics, visualization, 
and reporting capabilities. KNIME integrates nodes for machine learning, statistical data 
analysis, and interfaces to various scripting languages, for example, the statistical programming 
language R. KNIME’s functionality can be extended with nodes provided via an online 
repository (the so-called KNIME extensions). Our automated analysis workflow allows 
simultaneous calculation of a behavioral fingerprint for all analyzed molecules and to further 
process the data, e.g., by hierarchical clustering. Since the workflow has broad utility for 
behavioral analysis, it is made freely accessible on the KNIME Public Example Server as 
050_Applications/050021_PMR Analysis. 
 
Furthermore, to further characterize the potential of the PMR for mechanism prediction, we 
performed PMR analysis of 767 neuroactive compounds covering 14 different receptor classes 
(adrenergics, dopaminergics, serotonergics, opioids, sigma ligands, cholinergics, 
histaminergics, melatonin ligands, ionotropic glutamatergics, metabotropic glutamatergics, 
GABAergics, purinergics, adenosines, and ion channel ligands) using the KNIME workflow.  
Our results confirm the utility of the PMR assay to identify a broad range of neuroactive 
molecules. Moreover, the observations suggest that PMR can be useful for mechanism 
prediction for adrenergics, dopaminergics, serotonergics, metabotropic glutamatergics, opioids, 
and ion channel ligands. 
 
MATERIALS AND METHODS 
Zebrafish maintenance  
Adult zebrafish (Danio rerio) stocks of the AB strain (Zebrafish International Resource Center, 
Oregon, USA) were maintained at 28.0°C, on a 14/10 hour light/dark cycle under standard 
aquaculture conditions. Fertilized eggs were collected via natural spawning. Embryos and 
larvae were kept on a 14/10 hour light/dark cycle in embryo medium: 1.5 mM HEPES, pH 7.6, 
17.4 mM NaCl, 0.21 mM KCl, 0.12 mM MgSO4, and 0.18 mM Ca(NO3)2 in an incubator at 
28.0°C. All zebrafish experiments carried out were approved by the Ethics Committee of the 
University of Leuven (Ethische Commissie van de KU Leuven, approval number (P101/2010)) 
and by the Belgian Federal Department of Public Health, Food Safety & Environment (Federale 
Overheidsdienst Volksgezondheid, Veiligheid van de Voedselketen en Leefmilieu, approval 
number LA1210199). 
 
Compound libraries and compounds 
633 compounds from the Screen-Well Neurotransmitter Library (BML-2810-0100, Enzo Life 
Sciences), 71 compounds from the Screen-Well Ion Channel Ligand Library (BML-2805-0100, 
Enzo Life Sciences), 33 selected compounds from the Spectrum Collection library 
(MicroSource Discovery Systems Inc.), and 30 individually purchased compounds (Sigma-
Aldrich, Prestwick) were analyzed by the PMR assay. Positive controls isoproterenol and 
apomorphine were purchased from Sigma-Aldrich and diazepam was obtained from the 
pharmacy (Roche, Valium 10 mg/2 ml ampullas). 
 
Compound preparation 
Isoproterenol, diazepam, and apomorphine were dissolved in DMSO to 10 mM, 5 mM, 2.5 mM, 
and 1.25 mM concentrations and 100-fold diluted in the embryo’s swimming water (embryo 
medium) to final concentrations of 100 µM, 50 µM, 25 µM, and 12.5 µM with a final solvent 
concentration of 1% DMSO. 767 compounds were analyzed by the PMR assay at a 
concentration of 50 µM with a final solvent concentration of 0.5% or 1% DMSO. 737 
compounds were provided by compound libraries as 10 mM DMSO stocks (water was used as 
a solvent for DMSO insoluble compounds) and 200-fold diluted in the embryo’s swimming 
water to final concentrations of 50 µM (0.5% DMSO). 30 individually purchased compounds 
were prepared as 5 mM DMSO stocks and 100-fold diluted in the embryo’s swimming water 
to final concentrations of 50 µM (1% DMSO). Vehicle (VHC) treated controls were treated 
with 0.5% DMSO, 1% DMSO, or water in accordance with the final solvent concentration of 
the analyzed compounds. 
 
Photomotor response assay 
Protocol was adapted from Kokel and colleagues.1 The photomotor response of zebrafish 
embryos was investigated by automated behavioral tracking (Zebrabox, Viewpoint) at 30-32 
hours post-fertilization (hpf). Zebrafish embryos were placed in a 96-well plate in embryo 
medium at 27-29 hpf (prim-15 stage), followed by a dark incubation of 3 hours with VHC or 
compound prior to tracking, including 20 minutes of habituation in the Zebrabox chamber. 
Concurrent controls were run with each compound to avoid inter-plate variation. Exactly 5 
embryos were placed per well to obtain a cumulative photomotor response. Total motion was 
recorded for 30 seconds at 15 frames per second (fps) in fully dark conditions with a high 
intensity light pulse (5.2 mW/cm2, 38 000 lux) given at 10 and 20 seconds lasting one second. 
Raw data of total movement per well was used and is defined as the sum of all image pixel 
changes detected during the time interval of 0.067 seconds, corresponding to one frame. Total 
motion was plotted in function of time and average motion was plotted per time period. The 
PMR was divided in 8 time periods. The so-called pre-stimulus phase, at which embryos show 
basal activity, was considered as 1 time period (PRE; seconds 0-10). The latency phase, which 
occurs immediately after the first light stimulus, was considered as 1 period (L; seconds 10-11). 
The excitatory phase, at which embryos shake vigorously, was divided in three periods (E1; 
seconds 11-13, E2; seconds 13-16, E3; seconds 16-20). Finally, the refractory phase, at which 
embryos show a lower than basal activity, is triggered by the second light stimulus and was 
divided in three periods as well (R1; seconds 20-22, R2; seconds 22-25, R3; seconds 25-30). 
For control experiments with isoproterenol, diazepam, and apomorphine, data were pooled 
from three independent experiments with 4 to 6 replicate wells per condition. For screening of 
neuroactive molecules, data were pooled from 3 or 6 replicate wells per molecule. Replicate 
wells were scattered over the 96-well plate. The PMR assay was standardized for temperature 
at 28°C, including habituation and behavioral tracking in the Zebrabox, which was placed in an 
incubator for temperature control. Automated behavioral tracking was standardized for light 
intensity by the usage of only the 30 central wells of a 96-well plate, ensuring identical light 
intensity regardless of the position.  
 
Microscopic evaluation of toxicity 
The PMR assay was immediately followed by visual evaluation of the embryos by a light 
microscope to assess toxicity of pharmacological treatment. Overall morphology, heartbeat, and 
touch response was investigated. Overall morphology was considered as normal in case of a 
normal appearance. Overall morphology was considered as abnormal, in case of signs of 
necrosis, which was especially seen at the tip of the tail. We did not encounter other 
morphological abnormalities like edema or developmental defects. The heartbeat was 
considered as normal, reduced, or absent. The behavioral response of embryos to touch was 
investigated by touching the chorion of the embryo at the site of the yolk with a bold needle. 
Touch response was considered as normal (including hyperactivity), reduced, or absent. 
Compounds were scored as normal (N) if exposed embryos had a normal morphology, 
heartbeat, and touch response. Compounds were scored as sedative (S) if exposed embryos had 
a normal morphology, normal or reduced heartbeat, and a reduced or absent touch response. 
Compounds were scored as toxic (T) if exposed embryos had an abnormal morphology, or an 
absent touch response with absence of heartbeat. 
 
Behavioral fingerprints 
Behavioral fingerprints were calculated by an automated workflow using KNIME Analytics 
Platform 2.11.3. A behavioral fingerprint represents the embryonic motion during the 8 PMR 
periods by subsequent numeric values. Each period was described by the first (25% of motion, 
Q1) and third quantile (75% of motion, Q3), giving a total of 16 numeric values. For comparison 
with VHC treated embryos, pseudo Z-scores were calculated for each log-transformed quantile 
by the following formula:  
pseudo Z − score =
µ𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 − µ𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝜎𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 
 
The mean value (µ) of the control condition is subtracted from the mean value of the treatment 
condition and the result is divided by the standard deviation (σ) of the control condition to 
obtain the pseudo Z-score. The behavioral fingerprints consist of 16 subsequent pseudo Z-
scores, calculated from the Q1 and Q3 from each PMR period. The definition and calculation 
of behavioral fingerprints or barcodes is adapted from Kokel and colleagues.1,3 
 
KNIME Analytics Platform 
Supplemental Figure S1 shows the main window of the KNIME Analytics Platform. On the left 
the “KNIME Explorer” shows the available workflows. The “Node Repository” contains the 
available nodes. In the center an open workflow is shown. A description of the selected node is 
given at the right of the window. The “Console” is seen at the bottom which gives details about 
warnings and errors that occurred during workflow execution (Suppl. Fig. S1). 
 
A KNIME workflow is composed of multiple nodes that are connected by ports. Data is passed 
along the connections between ports in a table structure with columns (each having a certain 
type) and rows. The parameters of nodes and their documentation are available via a 
configuration dialog. More complex workflows, such as the one we developed and describe 
below, contain also loops and switches. Loops allow applying the same series of nodes to 
multiple input files one at a time and switches allow executing only certain branches of the 
workflow based on user-defined conditions. To further structure a workflow, KNIME provides 
the so-called meta-nodes to group a collection of nodes. Grouping into meta-nodes can be used 
to hide a complex series of nodes and instead provide a high-level view on the data flow. 
 
RESULTS 
PMR analysis of positive controls isoproterenol, diazepam, and apomorphine 
To validate our optimized PMR assay, three drugs with known PMR-modifying effects were 
analyzed, i.e., isoproterenol, diazepam, and apomorphine. These drugs were earlier shown by 
Kokel and colleagues to cause excitation, inhibition, and latency of the excitatory phase, 
respectively.1  
 
Embryos incubated for 3 hours with 100 µM isoproterenol demonstrated an overall excitation 
of the photomotor response in comparison with VHC treated controls. This increase in motion 
was observed to be significant at the pre-stimulus phase (p<0.01), latency phase (p<0.05), and 
first (p<0.001) and second (p<0.05) excitation period (Fig. 1A, B). Embryos incubated for 3 
hours with 100 µM diazepam demonstrated an overall inhibition of the PMR in comparison 
with VHC treated controls. This decrease in motion was observed to be significant at the pre-
stimulus phase (p<0.001), latency phase (p<0.01), and first (p<0.001) and second (p<0.001) 
excitation period (Fig. 1C, D). Finally, embryos incubated for 3 hours with 100 µM 
apomorphine demonstrated a complex altered PMR in comparison to VHC treated embryos. 
The PRE motion was lowered, no difference was seen in the E1 period, and a significant 
increase in motion was observed for the E2 (p<0.001), E3 (p<0.001), and R1 (p<0.01) period. 
These latter observations were due to the occurrence of a second excitation peak, delayed to the 
incidence of the first excitation peak. This excitation peak only slowly passed in comparison 
with the normal excitation peak of control embryos (Fig. 1E, F). Concentration dependency 
was observed for all phenotypes (Fig. 1G). Taken together, these observations suggest that our 
PMR assay can detect PMR-modifying effects very similarly to those reported by Kokel and 
colleagues.  
 
Generation of an automated KNIME workflow for large-scale PMR analysis  
For our large-scale PMR analysis of neuroactive molecules, behavioral analysis had to be rapid, 
easy, and automated. Therefore, a KNIME workflow was built to analyze the data recorded by 
the Zebrabox. It computes the pseudo Z-scores and behavioral fingerprints for each molecule, 
and finally performs hierarchical clustering of the pseudo Z-scores and generates a dendrogram. 
The workflow is rather complex, as it performs all steps from reading the raw data until the 
final dendrogram. In order to make it more readable it has therefore been divided into several 
sections using the meta-node concept mentioned in the materials and methods. The workflow 
is shown in Figure 2. For reasons of space we will only highlight the important parts. The 
complete workflow, including inline comments, can be downloaded from KNIME’s Public 
Example Server directly from within KNIME (login via the entry in the “KNIME Explorer” 
view).  
 
The workflow requires two types of input. The first input is the raw data, which consists of 
several CSV files (one per 96-well plate) containing raw measurements for all wells on the plate 
over the 30 seconds interval (about 28 000 rows per file). The data is divided into three columns: 
time, well ID (e.g., “c1”, “c2”), and the embryonic motion measurement. The workflow iterates 
over all files in the experiment’s directory and computes the behavioral fingerprint for each 
molecule (see below). The second input is a file that contains a mapping between the 
plates/wells and the treatment in each well (referred to as substance in the workflow), e.g., VHC 
or a certain molecule. Additionally it may contain manual annotations, indicating whether a 
well should be ignored in the further analysis, e.g., because the well was empty or no treatment 
was added.  
 
Computation of the behavioral fingerprints inside the “Calculate fingerprint” meta-node works 
as follows (Fig. 3A). First the raw input data is transformed from the three-column structure 
described above into a table with a column for each well and a row for each time point (“Data 
Transformation” meta-node). The values in the cells are the measurements. The “Unify 
Domains” meta-node ensures that the y-axes in the lines plots have the same scales and can 
therefore be directly compared. Figure 3B shows some plots generated by the “Line Plots” 
meta-node. The Numeric Binner assigns names to the time intervals (“segments”) as described 
above (e.g., “L”, “E1”, “R1”). The “Group Loop” iterates over the measurements in each of the 
segments separately. For each well/substance in each segment, we compute the 25% and 75% 
quantiles (Q1 and Q3, respectively) and use the logarithms of these values in subsequent steps 
(“Calculate Quartiles” meta-node). Figure 3C shows parts of the resulting table for segment 
“R3”. Finally, we compute the pseudo Z-scores based on the quartiles of the controls and the 
molecules, and transform the structure to obtain a row for each segment and a pseudo Z-score 
(Q1 and Q3) with the corresponding values for each molecule in the columns (Fig. 3D). This is 
the result of the outermost loop, which completes the computation of all values for all plates. 
Note also the “Check bad measurements” meta-node in the center of Figure 3A. This node 
provides an extra internal control to avoid the analysis of a plate when multiple control wells 
are ignored due to an error, e.g., a software error or manual error. It checks the manual 
annotations for all wells and if such plate occurs, it fails and will stop execution of the remaining 
workflow.  
 
The next step is to remove all columns/molecules with pseudo Z-scores below a certain 
threshold. The threshold can easily be set by the user via the configuration dialog of the “Filter 
substances” meta-node, without having to know the other details of the filtering. 
 
In the bottom part of the main workflow (Fig. 2) we first transpose the table so that each 
molecule is in a row and the pseudo Z-scores for the segments are in the columns. Next, we 
remove the segment ‘IGNORE’ that represents seconds just before and after the 30 second PMR 
period that are not taken into account. Then we compute a distance matrix (Euclidean distance) 
using the pseudo Z-scores as dimensions and perform hierarchical clustering with complete 
linkage. The final result is a dendrogram, including a heatmap, as shown in Figure 4 and 
discussed in the next sections.  
 
PMR analysis of 14 classes of neuroactive molecules 
A systematic analysis was done of 767 neuroactive molecules covering 14 different receptor 
classes (adrenergics, dopaminergics, serotonergics, opioids, sigma ligands, cholinergics, 
histaminergics, melatonin ligands, ionotropic glutamatergics, metabotropic glutamatergics, 
GABAergics, purinergics, adenosines, and ion channel ligands) to further characterize the 
neurological pathways that can alter PMR. Embryos were incubated either with vehicle (0.5 or 
1% DMSO) or with 50 µM of a certain molecule (final solvent concentration of 0.5 or 1% 
DMSO) for 3 hours prior to PMR analysis. PMR analysis was followed by microscopic 
evaluation of embryo morphology, heartbeat, and touch response, to assess toxicity of 
pharmacological treatment. A low rate of sedative (3.4%) and toxic (2.2%) compounds was 
observed, suggesting that 50 µM of most neuroactive compounds is well tolerated by zebrafish 
embryos during an acute exposure (Table 1).  
 
A PMR positive molecule was defined as a molecule that modifies the photomotor response 
such that its behavioral fingerprint contains at least one pseudo Z-score with an absolute value 
exceeding 3. At this critical value, 195 molecules were observed to be PMR positive, giving a 
true positive rate of 25.4% and a false negative rate of 74.6%. Thus, 25.4% of known 
neuroactive molecules alter PMR sufficiently at the analyzed concentration to be identified as 
neuroactive by the PMR assay. At a lower critical value of 2, 324 molecules were PMR positive, 
giving a true positive rate of 42.2% and a false negative rate of 57.8%. This lower stringency 
allows the detection of more than 40% of the neuroactive molecules at 50 µM. At a higher 
critical value of 5, 117 molecules were still observed to be positive, giving a true positive rate 
of 15.3% and a false negative rate of 84.7% (Table 1). These PMR positives alter the PMR so 
much that a difference in motion of at least 5 times the standard deviation of the control is seen. 
For further analysis the critical value of 3 was taken to consider only neuroactive molecules 
that alter PMR in a robust manner.  
 
Among PMR positive molecules, all neurological pathways are represented as molecules from 
all receptor classes were included. This observation confirms the utility of PMR to detect a 
broad range of neuroactive molecules and suggests the involvement of these pathways in PMR 
regulation.   
 
Hierarchical clustering of PMR positive molecules 
To characterize the classes of neuroactive molecules that can induce a distinct PMR phenotype, 
hierarchical clustering of behavioral fingerprints of the 195 PMR positive molecules was done 
(Fig. 4). A cluster was considered to be enriched with molecules from a certain neurological 
pathway if more than one third of the molecules belongs to a single receptor class and the cluster 
has a minimum size of 7 fingerprints. This was determined in a top-down approach evaluating 
the 30 most distinct clusters of the heatmap as indicated by the workflow. 8 clusters were 
observed to be enriched with a certain class of molecules. These clusters are indicated by 
numbers 1-8 in Figure 4.  
 
Cluster 1 is enriched with behavioral fingerprints from opioids. 5 out of 7 molecules are opioid 
receptor ligands. These show a higher activity in the E1 and E2 period in comparison to control 
behavior and a reduced activity in periods E3, R1, R2, and R3 (cluster 1; Suppl. Fig. S2). 
Cluster 2 is enriched with ligands from metabotropic glutamatergic receptors. 4 out of 10 
molecules belong to this class of receptors, 3 of them are receptor agonists. These molecules 
show a behavioral fingerprint with decreased activity mainly in periods E2 and E3, but also in 
R1-3 (cluster 2; Suppl. Fig. S2). Cluster 4 is also enriched with ligands from metabotropic 
glutamatergic receptors, but all are receptor antagonists. 4 out of 9 molecules belong to this 
class of receptors and show a reduced activity especially in the PRE, E1, and E2 period in 
comparison to controls (cluster 4; Suppl. Fig. S2). 3 of these molecules have the mGlu5 
receptor as target. Cluster 3 is enriched with ligands from adrenergic receptors. 10 out of 23 
molecules belong to this class of receptors, 8 of them are receptor agonists and 7 molecules are 
α receptor ligands. They show a behavioral fingerprint with an overall increased activity in 
comparison to controls (cluster 3; Suppl. Fig. S2). Cluster 5 is enriched with ligands from 
dopaminergic receptors. 6 out of 8 molecules belong to this receptor class, 5 of them are 
receptor agonists. Their behavioral fingerprints show a decreased activity especially in the PRE 
and E1 phase (cluster 5; Suppl. Fig. S2). Cluster 8 is also enriched with ligands from 
dopaminergic receptors. 11 out of 26 molecules belong to this class of receptors, both agonists 
and antagonists. 6 of them are D4 receptor ligands. Their behavioral fingerprints show also a 
decreased activity in the PRE phase, but in comparison to cluster 5, the activity in the E1 period 
is much more decreased (cluster 8; Suppl. Fig. S2). Cluster 6 is enriched with behavioral 
fingerprints from different types of ion channel ligands. 12 out of 33 molecules belong to this 
type of ligands and 8 of them act on calcium channels. Their behavioral fingerprints show a 
decreased motion during the E1 and E2 period and a moderate decrease or increase in motion 
in periods E3-R3 (cluster 6; Suppl. Fig. S2). Finally, cluster 7 is part of cluster 6. This smaller 
cluster is also enriched with ligands from serotonergic receptors. 5 out of 13 molecules belong 
to this receptor class. Their behavioral fingerprints are very similar to those from cluster 6, but 
this subset shows a more decreased activity in the E1 and E2 period (cluster 7; Suppl. Fig. S2).  
 
In summary, ligands from the following classes of receptors were observed to induce a distinct 
PMR phenotype: adrenergics, dopaminergics, serotonergics, metabotropic glutamatergics, 
opioids, and ion channel ligands. This means that sigma ligands, cholinergics, histaminergics, 
melatonin ligands, ionotropic glutamatergics, GABAergics, purinergics, and adenosines seem 
to fail to induce a distinct PMR phenotype despite of their strong PMR-modifying effects. This 
data suggests that PMR is useful for mechanism prediction only within the above first 
mentioned neurological pathways. 
 
DISCUSSION 
With this study a systematic PMR analysis was done of the different neurological pathways by 
analysis of 767 ligands that cover 14 receptor classes. Our results confirm the utility of the PMR 
assay to identify a broad range of neuroactive molecules, as was demonstrated by Kokel and 
colleagues.1 The use of the PMR for mechanism prediction was further investigated and is 
suggested to be limited to adrenergics, dopaminergics, serotonergics, metabotropic 
glutamatergics, opioids, and ion channel ligands. Our data thereby confirms the study by Kokel 
and colleagues who also reported phenotypical clusters for adrenergic and dopaminergic 
agonists.1 Furthermore, we expand their findings with the report of distinct phenotypical 
clusters for serotonergics, metabotropic glutamatergics, opioids, and ion channel ligands. In 
contrast to the study by Kokel we did not identify a cluster enriched with adenosine receptor 
antagonists. This is likely due to differences in protocol, e.g., incubation time (3 hours versus 
2-10 hours), but can also be due to the more sensitive detection of embryonic motion by our 
set-up (detection of motion in the entire well versus detection of motion at 6 lines covering the 
well).  
 
The identification of phenotypic clusters from adrenergics, dopaminergics, serotonergics, 
metabotropic glutamatergics, opioids, and ion channel ligands suggests that within these classes 
new molecules can be identified and the mechanism can be predicted by phenotypic similarity. 
This allows the use of PMR not only to screen for neuroactivity in general, but also to screen 
for a certain class of ligands, indicating their potential therapeutic use. Our data suggests that 
this is not possible for all neurological pathways, but limited to the receptor classes mentioned 
above. Concerning the detail of mechanism prediction, an indication for agonistic or 
antagonistic activity is clear in 4 of the 8 clusters, but an indication for a specific target or 
receptor is not so common. In our data set only 4 targets were highly present in their respective 
clusters, i.e., the mGlu5 receptor, α receptor, calcium channel, and the D4 receptor. This is not 
surprising as the annotated activity of a molecule will not always reflect its activity on the 
zebrafish target. This is due to possible differences between zebrafish and human receptors and 
is referred to as the zebrafish annotation problem.4 Nevertheless, PMR phenotyping can be used 
for target prediction when screening for molecules without a predefined target. This is 
suggested by our data and was already demonstrated by Kokel and colleagues who identified 
novel acetylcholinesterase inhibitors by phenotypic similarity.1    
 
The absence of phenotypic clusters from the other classes of ligands is due to the absence of 
distinct PMR phenotypes for each class and can have multiple causes. First, ligands from 
different classes can (in)directly affect the same PMR-regulating neurological pathway or affect 
different neurological pathways with a similar PMR-modifying effect. Second, there can be a 
large variation between ligands from the same receptor class in terms of conservation of the 
drug target in zebrafish, optimal test concentration, or drug absorption which all can result in 
different PMR phenotypes. Third, as many neuroactive ligands have multiple targets it is 
possible that these ligands do not induce a similar PMR phenotype within a certain class. 
 
Furthermore, we observed a high false negative rate for PMR analysis at the analyzed 
concentration of 50 µM and after an acute exposure of 3 hours. Analysis of multiple 
concentrations and exposure times will increase the number of true positives, but this will also 
largely reduce the throughput. Moreover, as many neuroactive drugs act on multiple targets it 
can be expected to detect less specific behavioral fingerprints when analyzing compounds at 
high concentrations. Therefore, ideally, a concentration-response analysis should be performed 
for each compound to allow improved clustering of the fingerprints based on cross-
concentration behavioral similarities within receptor classes. Such an approach would not only 
reduce the false negative rate, but could also improve phenotype-based mechanism predication. 
Besides the analysis of compounds at a single concentration and exposure time, other causes 
for the observation of false negatives in this study could be: malabsorption of the drug, failure 
of the immature metabolism to activate prodrugs, absence of the functional target in zebrafish 
or in the immature brain, or the drug target is not involved in PMR regulation.  
 
For improved understanding of our results it is important to know which neurological pathways 
are present in the immature brain of the zebrafish embryo. The PMR occurs between 30 and 40 
hpf, while the light-evoked refractory phase is already observed from 27 hpf onwards.5 At these 
stages primary neurogenesis is ongoing until 48 hpf when secondary neurogenesis initiates. 
Primary neurogenesis involves the transient establishment of an early sensorimotor circuit that 
allows motor behaviors. These neurons were reported to include glutamatergic, GABA-ergic, 
cholinergic, and glycinergic neurotransmission at 24 hpf.6–8 Furthermore, spatiotemporal 
expression of aminergic innervation in the developing zebrafish embryo demonstrated 
dopaminergic, (nor)adrenergic, and serotonergic neurotransmission at 24 hpf. Adrenergic or 
noradrenergic neurons were observed in the hindbrain in the developing locus coeruleus and by 
36 hpf as well in the medulla oblongata. Dopaminergic neurons were also observed in the locus 
coeruleus and furthermore in the posterior tuberculum that is localized in the diencephalon 
(forebrain). Serotonergic neurons were also observed in the posterior tuberculum and by 32 hpf 
in the spinal cord as well.9,10 Finally, spatiotemporal expression of the zebrafish opioid 
receptors shows a wide distribution in the central nervous system at 24 and 48 hpf.11,12 The 
early establishment of the main neurotransmission systems before and by the time of PMR 
initiation is in accordance with the phenotypical clusters we could detect. Moreover, the early 
aminergic innervation of the spinal cord by the hindbrain, which is described in a study by 
McLean and Fetcho9, is in line with the sudden shift in motor behavior from low-frequent touch 
responses until 26 hpf to high-frequent swimming from 28 hpf onwards.8 This swimming 
behavior is involved in the PMR and was shown to be driven by photosensitive hindbrain 
neurons.5  
 
Expression studies have also demonstrated the early presence of adenosine13, purinergic14,15, 
and melatonin16 receptors in the central nervous system of the developing zebrafish embryo at 
24 hpf. This is in line with the identification of multiple PMR positive molecules from these 
receptor classes. We also identified PMR positive molecules that act through histamine or sigma 
receptors, suggesting their functionality at these early stages. The presence of these receptors 
in the central nervous system at 30 hpf has not yet been reported, to our knowledge, as only few 
studies have been done that did not include spatiotemporal investigations at this early stage.17–
19  
 
Furthermore, with this study a KNIME workflow was built to analyze behavioral data in a rapid 
and easy manner. The workflow is designed to calculate behavioral fingerprints for hundreds 
up to thousands of treatments at the same time, and finally to hierarchically cluster these 
fingerprints. This workflow enables everyone, without the need for programming skills or IT 
experience, to analyze behavioral data. Parameters can easily be changed through the 
configuration button of each node, e.g., the type of distance measure, the type of linkage, and 
the critical pseudo Z-score value can be changed. Moreover, the workflow is designed such that 
nodes can easily be removed, added or changed to alter the type of analysis.  
 
Finally, in this study we focused on the applicability of the photomotor response, which is a 
non-visual light-driven behavioral response. Other types of behavioral responses to neuronal 
stimuli can also be used for neuroactive drug discovery, e.g., visual light-driven responses, 
auditory responses. One example is the automated rest/wake behavioral assay that was reported 
by Rihel and colleagues for phenotype-based target prediction and drug discovery.20 The 
challenge becomes to correlate these different types of neuronal responses in drug screening 
strategies. One possibility is to generate a battery of different behavioral assays and to combine 
the results as different bars within a descriptive barcode. Such an approach allows a more 
detailed level of phenotypic description and is expected to improve drug discovery and target 
prediction. This principle is referred to as behavioral barcoding and has been previously 
described.3   
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TABLE 
Table 1. PMR analysis of neuroactive compounds  
 Number of molecules Rate (%)  
Total 767   
Normal (N) 724 94.4  
Sedative (S) 26 3.4  
Toxic (T) 17 2.2 toxicity rate 
Pseudo Z-score ≥ |2|    
positives  324 42.2 true positive rate 
negatives  443 57.8 false negative rate 
Pseudo Z-score ≥ |3|    
positives  195 25.4 true positive rate 
negatives  572 74.6 false negative rate 
Pseudo Z-score ≥ |5|    
positives  117 15.3 true positive rate 
negatives  650 84.7 false negative rate 
 
LEGENDS 
Figure 1. PMR of 30-32 hpf zebrafish embryos incubated with positive controls isoproterenol, 
diazepam, and apomorphine. Embryos were treated for 3 hours with vehicle (VHC) or 100 µM 
of drug. (A, C, E) Total motion of the embryos as function of time. (B, D, F) Mean motion of 
the embryos as function of 8 PMR periods. (G) Mean behavioral fingerprints of embryos treated 
with 12.5, 25, 50, and 100 µM of isoproterenol, diazepam, and apomorphine, respectively. (A-
F) Data are expressed as mean ±SEM. Statistical analysis was done by two-way ANOVA 
(GraphPad Prism 5). Significance levels: * p<0.05; ** p<0.01; *** p<0.001.  
 
Figure 2. KNIME workflow for PMR analysis. The workflow structure is using meta-nodes in 
order to make it more readable and easier to maintain.   
 
Figure 3. A detailed view of the meta-node that computes the behavioral fingerprints. (A) 
Inside view of the meta-node ‘Calculate fingerprint for plate’. The meta-node is again divided 
into several nested meta-nodes. (B) Result table of the meta-node ‘Line Plots’. Line plots show 
the embryonic motion in time in a certain well. (C) Result table of the meta-node ‘Calculate 
Quartiles’ showing some computed quantiles for segment R3. (D) Final result table showing 
the pseudo Z-scores for tested molecules. 
 
Figure 4. Hierarchical clustering of PMR positive molecules. Behavioral fingerprints of PMR 
positive molecules were clustered by complete linkage of the distance matrix (Euclidean 
distance). (A) Heatmap and dendrogram is shown. Numbers 1-8 indicate clusters that are 
enriched with molecules from a single receptor class. (B) Color scales of the heatmap are given 
for the first (Q1) and third quantile (Q3) for all PMR periods. PRE, pre-stimulus phase; L, 
latency phase; E1, excitatory period 1; E2, excitatory period 2; E3, excitatory period 3; R1, 
refractory period 1; R2, refractory period 2; R3, refractory period 3.   
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An automated KNIME workflow for large-scale PMR analysis 
The KNIME workflow for PMR analysis is part of the supplemental material and can also be 
downloaded from the KNIME Public Example Server as 050_Applications/050021_PMR 
Analysis. The workflow requires at least KNIME Analytics Platform 2.11.1 with the following 
additional extensions: 
- KNIME Math Expression (JEP) 
- KNIME Nodes to create KNIME Quick Forms 
- KNIME XLS Support 
- KNIME JFreeChart 
- HiTS experimental features (from https://code.google.com/p/hits/wiki/Install) 
 
KNIME Analytics Platform 
 
Figure S1. Screenshot of the KNIME Analytics Platform with an open workflow. 
 
 
Phenotypical clusters enriched with molecules from a single receptor class 
 
 
 
 
 
 
  
 
 
 Figure S2. Detailed view of phenotypical clusters that are enriched with molecules from a 
single receptor class. A detailed view is given from clusters 1-8, indicated in the dendrogram 
from Figure 4. The cluster number is given in column 1. The behavioral fingerprint of each 
molecule within each cluster is given in column 2. The compound name is given in column 3. 
The receptor class of each compound is given in column 4, and the receptor/target of molecules 
that are enriched in a cluster is given between parentheses. The scores normal (N), sedative (S), 
or toxic (T) which were given to each compound after microscopic evaluation of toxicity is 
given in column 5. (1), -1,3,4-tricarboxylic acid; (2), oxepin maleate; δ, delta receptor; К, kappa 
receptor; µ, mu receptor; α, α receptor; β, β receptor; DRI, dopamine reuptake inhibitor; 
COMT-I, catechol-O-methyl transferase inhibitor; DOPA, dopaminergic; chol, cholinergic; 
melat, melatonin; hist, histamine; mGlu, metabotropic glutamatergic; iGlu, ionotropic 
glutamatergic; A, adrenergic; GABA, GABAergic; adenos, adenosine; 5-HT, serotonergic; K, 
potassium; Ca, calcium; Na, sodium; Cl, chloride; iCa, intracellular calcium; +, agonist; -, 
antagonist; ±, partial agonist. 
 
 
 
 
